Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Lyden

Showing results (61-70 of 110) with videos related to

Pageof 11
Sort By:
BMC Medical Research Methodology|November 22, 2023
The difference between concealment and blinding in clinical trials and why both are important. A reply to Garg and Mickenautsch, BMC Medical Research Methodology (2022) 22:17Patrick Lyden, Joseph Broderick, James Grotta, et al.
Stroke (Hoboken, N.J.)|January 26, 2026
Validation of the National Institutes of Health Stroke Scale in Intracerebral HemorrhageWendy Dusenbury, Georgios Tsivgoulis, Jason Chang, et al.
Current Pharmaceutical Design|December 31, 2013
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteersPatrick Lyden, Howard Levy, Sara Weymer, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|March 5, 2011
Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhageBrett Cucchiara, Scott Kasner, David Tanne, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 28, 2024
Differential Vulnerability and Response to Injury among Brain Cell Types Comprising the Neurovascular UnitPadmesh Rajput, Allison Brookshier, Shweta Kothari, et al.
Frontiers in Neurology|March 31, 2018
Treatment Modality and Quality Benchmarks of Aneurysmal Subarachnoid Hemorrhage at a Comprehensive Stroke CenterWengui Yu, Tapan Kavi, Tamara Majic, et al.
Stroke|November 15, 2011
Response of blood pressure and blood glucose to treatment with recombinant tissue-type plasminogen activator in acute ischemic stroke: evidence from the virtual international stroke trials archiveDaniel M Kerr, Rachael L Fulton, Peter Higgins, et al.
Stroke|June 23, 2020
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of TenecteplasePurba Mukherjee, Patrick Lyden, José A Fernández, et al.
Annals of Emergency Medicine|March 30, 2005
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke StudyThomas Kwiatkowski, Richard Libman, Barbara C Tilley, et al.
Stroke|June 28, 2008
Serum calcium as prognosticator in ischemic strokeBruce Ovbiagele, Sidney Starkman, Philip Teal, et al.
Pageof 11

Showing results (61-70 of 110) with videos related to

Sort By:
Pageof 11
BMC Medical Research Methodology|November 22, 2023
The difference between concealment and blinding in clinical trials and why both are important. A reply to Garg and Mickenautsch, BMC Medical Research Methodology (2022) 22:17Patrick Lyden, Joseph Broderick, James Grotta, et al.
Stroke (Hoboken, N.J.)|January 26, 2026
Validation of the National Institutes of Health Stroke Scale in Intracerebral HemorrhageWendy Dusenbury, Georgios Tsivgoulis, Jason Chang, et al.
Current Pharmaceutical Design|December 31, 2013
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteersPatrick Lyden, Howard Levy, Sara Weymer, et al.
International Journal of Stroke : Official Journal of the International Stroke Society|March 5, 2011
Validation assessment of risk scores to predict postthrombolysis intracerebral haemorrhageBrett Cucchiara, Scott Kasner, David Tanne, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|March 28, 2024
Differential Vulnerability and Response to Injury among Brain Cell Types Comprising the Neurovascular UnitPadmesh Rajput, Allison Brookshier, Shweta Kothari, et al.
Frontiers in Neurology|March 31, 2018
Treatment Modality and Quality Benchmarks of Aneurysmal Subarachnoid Hemorrhage at a Comprehensive Stroke CenterWengui Yu, Tapan Kavi, Tamara Majic, et al.
Stroke|November 15, 2011
Response of blood pressure and blood glucose to treatment with recombinant tissue-type plasminogen activator in acute ischemic stroke: evidence from the virtual international stroke trials archiveDaniel M Kerr, Rachael L Fulton, Peter Higgins, et al.
Stroke|June 23, 2020
3K3A-Activated Protein C Variant Does Not Interfere With the Plasma Clot Lysis Activity of TenecteplasePurba Mukherjee, Patrick Lyden, José A Fernández, et al.
Annals of Emergency Medicine|March 30, 2005
The impact of imbalances in baseline stroke severity on outcome in the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke StudyThomas Kwiatkowski, Richard Libman, Barbara C Tilley, et al.
Stroke|June 28, 2008
Serum calcium as prognosticator in ischemic strokeBruce Ovbiagele, Sidney Starkman, Philip Teal, et al.
Pageof 11